European governments should sue Roche and prescribers should boycott its drugs

BMJ (Online)

Volumn 345, Issue 7883, 2012, Pages

  Gtøzsche, Peter C ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PARACETAMOL; PLACEBO; ZANAMIVIR;

ACCESS TO INFORMATION; DRUG APPROVAL; DRUG EFFECT; DRUG INDUSTRY; EUROPE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; LETTER; MEDICAL RESEARCH; MEDICOLEGAL ASPECT; PANDEMIC INFLUENZA; POLITICAL PARTICIPATION; PRESCRIPTION; PRIORITY JOURNAL; SEASONAL INFLUENZA; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG INDUSTRY; DRUG PRESCRIPTIONS; EUROPE; GOVERNMENT; OSELTAMIVIR; RESEARCH DESIGN;

EID: 84869174502     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e7689     Document Type: Letter

References (3)

1. Doshi P. Neuraminidase inhibitors: the story behind the Cochrane review. BMJ 2009;339:b5164.
2. Cohen D, Carter P. WHO and the pandemic flu "conspiracies." BMJ 2010;340:c2912.
3. Godlee F. Open letter to Roche about oseltamivir trial data. BMJ 2012;345:e7305. (29 October.)